Associated tags: Medicine, OGM, Patient, Spectrum, Biology, Genome, Software, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”).
Key Points:
- SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”).
- As previously announced, the Company was notified by Nasdaq on May 30, 2023 that it was not in compliance with the Minimum Bid Price Requirement.
- The notification letter noted that for the last 10 consecutive business days, from August 7, 2023 to August 18, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater, and thus the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.
Insurance,
Accreditation,
College,
CAP,
Biotechnology,
National Voluntary Laboratory Accreditation Program,
Doctor of Philosophy,
CLIA,
Laboratory,
FACMG,
SAN,
Quality control,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
OGM,
Food,
Pharmaceutical industry SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.
Key Points:
- SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.
- CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP.
- CAP accreditation is often required for a clinical service provider to become part of insurance companies’ preferred provider networks for reimbursement.
- “I want to congratulate Alka and the team at Bionano Labs for achieving this milestone.
Quest Diagnostics,
Health,
Workflow,
FedEx,
Genomics,
Health care,
AIG,
Strategic planning,
Doctor of Philosophy,
A&P,
SAN,
CFO,
Cytogenetics,
Management,
Quest,
United Airlines SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023.
Key Points:
- SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023.
- Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role.
- She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth.
- Prior to Northern Data AG, Ms. Kama was Chief Financial Officer, East Region and Healthcare IT at Quest Diagnostics, Quest’s largest region, where she drove market expansion and operational efficiencies.
Diamond,
CGC,
Court of general sessions,
University,
Augusta University,
Workflow,
Genomics,
NGS,
University of Washington,
Cancer,
Bone marrow,
Research,
Oxford University Hospitals NHS Foundation Trust,
International Cancer Genome Consortium,
MD Anderson Cancer Center,
Chemistry,
SAN,
Annual general meeting,
California Hospital Medical Center,
Children's Hospital Los Angeles,
Hospital,
Cytogenetics,
Leukemia,
Panel discussion,
Nationwide,
OGM,
Very important person,
Medical device,
Vaccine,
Medical imaging CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research.
Key Points:
- CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research.
- During this interactive session, experts will discuss their experience implementing OGM, key applications, and potential implications for future clinical research and medical guidelines.
- Thirteen separate scientific presentations highlighting OGM as a novel technique in cancer research will be given at the conference.
- In addition, three posters featuring results from OGM applications in cytogenetics and cancer research will be presented at the conference.
IRD,
FISH,
Workflow,
Stanford University,
ISSCR,
Genomics,
Aberration,
NGS,
KT,
Cancer,
SVS,
GAAP,
Research,
Retina,
Doctor of Philosophy,
Sale,
Regenerative medicine,
Radboud University Medical Center,
Chemistry,
Congress,
Acquisition,
Publication,
European,
SAN,
EHA,
Antonio Strati,
Cytogenetics,
Growth,
Hospital,
OGM,
Conference,
Total,
DSM-IV codes,
Bone marrow,
Cryptocurrency,
Video game,
Pharmaceutical industry,
Vaccine GAAP gross margin for the second quarter of 2023 was 27%, compared to 22% from the second quarter of 2022.
Key Points:
- GAAP gross margin for the second quarter of 2023 was 27%, compared to 22% from the second quarter of 2022.
- Second quarter 2023 non-GAAP¹ gross margin was 29%, compared to 22% from the second quarter of 2022.
- Second quarter 2023 GAAP operating expense was $41.5 million, compared to $33.6 million in the second quarter of 2022.
- Second quarter 2023 non-GAAP operating expense was $34.6 million, compared to $26.3 million in the second quarter of 2022.
The Company’s common stock will trade under a new CUSIP number, 09075F 305, effective August 7, 2023, and remain listed on the Nasdaq Capital Market under the symbol “BNGO.” The reverse stock split reduces the number of shares of common stock issuable upon the conversion of the Company’s outstanding shares of preferred stock, if any, and the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the conversion and exercise prices of such preferred stock, stock options, restricted stock units and warrants.
Key Points:
- The Company’s common stock will trade under a new CUSIP number, 09075F 305, effective August 7, 2023, and remain listed on the Nasdaq Capital Market under the symbol “BNGO.” The reverse stock split reduces the number of shares of common stock issuable upon the conversion of the Company’s outstanding shares of preferred stock, if any, and the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the conversion and exercise prices of such preferred stock, stock options, restricted stock units and warrants.
- The reverse stock split impacts all holders of the Company’s common stock proportionally and will not impact any stockholder’s percentage ownership of the Company common stock (except to the extent the reverse stock split results in any stockholder owning only a fractional share).
- Bionano has chosen its transfer agent, American Stock Transfer & Trust Company, LLC (“AST”), to act as exchange agent for the reverse stock split.
- Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.
Key Points:
- SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.
Bionano TOUR provides an immersive in-person experience for attendees, combining informative demonstrations of the OGM workflow, the Ionic® system and VIA™ software from internal Bionano experts with presentations from current OGM users who have implemented the workflow for research in hematological malignancies, genetic disease, cell bioprocessing, and other applications.
Key Points:
- Bionano TOUR provides an immersive in-person experience for attendees, combining informative demonstrations of the OGM workflow, the Ionic® system and VIA™ software from internal Bionano experts with presentations from current OGM users who have implemented the workflow for research in hematological malignancies, genetic disease, cell bioprocessing, and other applications.
- "Bionano Symposium, which gathers the global community of OGM users and prospective users in a virtual event that lasts for a week in January, has been enormously successful in showing how the community uses OGM in their research.
- TOUR takes that same level of in-depth OGM experience with users to live, in-person events offering engagement with OGM experts to existing users.
- TOUR also provides the opportunity for new potential OGM users to learn what OGM is all about."
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Key Points:
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Hematologic disease,
Workflow,
Genomics,
NGS,
Cancer,
Research,
Doctor of Philosophy,
SAN,
OGM,
VIA,
DSM-IV codes,
Medical imaging,
Retail,
Stratis (configuration daemon) The VIA™ software replaces NxClinical™ software with a completely new platform for visualization, interpretation and reporting for hematologic malignancies across the main data types used in cytogenomics today – OGM, microarray and NGS.
Key Points:
- The VIA™ software replaces NxClinical™ software with a completely new platform for visualization, interpretation and reporting for hematologic malignancies across the main data types used in cytogenomics today – OGM, microarray and NGS.
- VIA further incorporates these data into an intuitive and powerful workflow for hematologic malignancies.
- Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume users.
- “We are pleased to announce two exciting new products that we believe will accelerate adoption of OGM by higher volume users and expand utilization: the Stratys system for OGM and our VIA software with a workflow for hematologic malignancies.
